Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.

Anti-CGRP therapies are important for preventing migraines. This study looked at how long patients stay on these treatments. It also examined why some patients stop using them. Researchers gathered data from various studies to understand treatment persistence over 3, 6, and 12 months. They found that many patients do not continue treatment long-term. The reasons for discontinuation varied, including side effects and lack of effectiveness. The findings highlight that while anti-CGRP therapies are widely used, many patients stop taking them. Understanding these reasons helps improve treatment strategies. Better persistence could lead to fewer migraines and improved quality of life. This research emphasizes the need for ongoing support and monitoring for patients on these therapies. Overall, the study provides valuable insights into real-world patient experiences with anti-CGRP treatments for migraine prevention. Clinical relevance: This research highlights the need for improved patient support to enhance treatment adherence for anti-CGRP therapies in migraine management.